Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06962891Active Not Recruiting

Validation of a Proteomic Biomarker to Predict Progression of Chronic Kidney Disease

Role: collaborator

NCT04547114Unknown

Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects

Role: lead

NCT04282135Completed

Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling

Role: lead

NCT04276025Completed

Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma

Role: lead

All 4 trials loaded